NRXS vs REGN · rev $3.6M vs P/E 14, rev $4.29B
Neuraxis, Inc. (NRXS) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Neuraxis, Inc. (NRXS) is a biotechnology company listed on AMEX.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported NRXS revenue for 2025-12-31 was $3.6M. Net income was -$7.8M. Revenue was up 32.9% from 2024-12-31 to 2025-12-31. NRXS currently screens at market cap $83.1M.
Latest reported REGN revenue for 2026-06-30 was $4.29B. Net income was $1.30B. Revenue was up 19.0% from 2026-03-31 to 2026-06-30. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
NRXS currently screens at market cap $83.1M. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the NRXS and REGN stock pages for the full models.
Not investment advice.